Chemours (NYSE:CC) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Wednesday.
Other analysts have also issued research reports about the stock. BMO Capital Markets cut their price objective on shares of Chemours from $68.00 to $58.00 and set an “outperform” rating on the stock in a research note on Monday, November 5th. They noted that the move was a valuation call. Citigroup reaffirmed a “buy” rating and set a $43.00 price objective on shares of Chemours in a report on Wednesday. Barclays reissued a “buy” rating and issued a $48.00 price target on shares of Chemours in a research note on Tuesday, January 15th. Susquehanna Bancshares decreased their price target on shares of Chemours from $65.00 to $44.00 and set a “positive” rating on the stock in a research note on Monday, November 5th. Finally, Zacks Investment Research cut shares of Chemours from a “hold” rating to a “sell” rating in a research report on Friday, January 4th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $48.13.
Shares of CC opened at $37.62 on Wednesday. Chemours has a fifty-two week low of $25.17 and a fifty-two week high of $53.25. The company has a market capitalization of $6.28 billion, a PE ratio of 6.63, a price-to-earnings-growth ratio of 0.54 and a beta of 2.32. The company has a debt-to-equity ratio of 3.88, a current ratio of 1.93 and a quick ratio of 1.26.
In other Chemours news, Director Richard H. Brown acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were acquired at an average cost of $28.60 per share, for a total transaction of $286,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.75% of the stock is owned by insiders.
Hedge funds have recently made changes to their positions in the company. Bank of Montreal Can grew its holdings in Chemours by 15.0% during the third quarter. Bank of Montreal Can now owns 141,454 shares of the specialty chemicals company’s stock worth $5,579,000 after acquiring an additional 18,502 shares during the period. Andra AP fonden lifted its holdings in Chemours by 16.2% in the 3rd quarter. Andra AP fonden now owns 131,300 shares of the specialty chemicals company’s stock worth $5,178,000 after purchasing an additional 18,300 shares during the last quarter. Cornerstone Wealth Management LLC lifted its holdings in Chemours by 22.4% in the 3rd quarter. Cornerstone Wealth Management LLC now owns 19,460 shares of the specialty chemicals company’s stock worth $355,000 after purchasing an additional 3,560 shares during the last quarter. IFM Investors Pty Ltd lifted its holdings in Chemours by 17.6% in the 3rd quarter. IFM Investors Pty Ltd now owns 9,578 shares of the specialty chemicals company’s stock worth $378,000 after purchasing an additional 1,431 shares during the last quarter. Finally, AMG National Trust Bank increased its position in Chemours by 8.8% in the 3rd quarter. AMG National Trust Bank now owns 25,456 shares of the specialty chemicals company’s stock worth $1,004,000 after buying an additional 2,049 shares during the period. Institutional investors and hedge funds own 78.89% of the company’s stock.
Chemours Company Profile
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.